Clinical Trials

Multiple clinical trials evaluate conditions involving redox balance, metabolic disorders, and vascular function, specifically targeting glucose-6-phosphate dehydrogenase deficiency, oxidative stress, dyslipidemias, metabolic syndrome, and alcoholism. Ranging from unassigned designs to Phase II evaluations, protocols investigate key parameters such as carbohydrate metabolism and pulmonary outcomes. Sponsored by academic institutions, medical centers, and government bodies—including Emory University, the University of Thessaly, and the National Institute on Alcohol Abuse and Alcoholism—these studies encompass completed, not yet recruiting, terminated, and unknown recruitment statuses.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05571748 Not yet recruiting
G6PD Deficiency|Carbohydrate Metabolism Disorder|Oxidative Stress
University of Thessaly
2023-02 Not Applicable
NCT05449249 Completed
Healthy|Periodontitis
Buchinger Wilhelmi Development & Holding GmbH|Buchinger Wilhelmi Clinic|University of Geneva Switzerland|King''s College London|ETH Zurich (Switzerland)
2022-09-01 Not Applicable
NCT04763499 Terminated
Vascular Dilation
University of California Davis
2021-12-01 Not Applicable
NCT04909489 Unknown status
Traditional Chinese Medicine|Dyslipidemias|Syndrome
Dongzhimen Hospital Beijing
2021-04-21 --
NCT04483011 Unknown status
Metabolic Syndrome|Premature Aging
Bioenergy Life Science Inc.|KGK Science Inc.|University of Washington
2019-10-25 Not Applicable
NCT03060772 Terminated
Alcoholism
Emory University|National Institute on Alcohol Abuse and Alcoholism (NIAAA)
2018-01-03 Phase 2

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Triphosphopyridine nucleotide disodium salt product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Triphosphopyridine nucleotide functions as an essential coenzyme and electron carrier by reversibly cycling between its oxidized (NADP+) and reduced (NADPH) states to modulate cellular redox reactions and biosynthetic cascades. This electron transfer maintains enzymatic antioxidant defenses and metabolic pathways, thereby counteracting cellular oxidative injury in clinical conditions such as G6PD deficiency and metabolic syndrome.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.